BIOBADASER cohort showing risk of incident cancer in rheumatic disease and previous malignancy was not difference between TNFi and other biologics/tsDMARDs. Need bigger numbers (esp with JAKi) to really reassure.
@RheumNow ABST0267 #ACR22 #ACRBest
https://t.co/0YutuCBOb8 https://t.co/btYrCA6UDh
Links:
Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheuma…
https://tinyurl.com/2e3jmnr4
12-11-2022
